Cancer · 2023 · 16 citations · 20 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmunotherapy For Breast CancerTumor Microenvironment ModulationImmune Checkpoint Blockade CombinationsImmune Receptor SequencingProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsProgrammed Cell Death Protein 1 RegulationT Cell Receptor SequencingTriple-negative Breast Cancer ImmunotherapyTumor Microenvironment Effects
BACKGROUND: Immune-checkpoint blockade (ICB) therapy shows promise for treating aggressive triple-negative breast cancer (TNBC). However, only some patients benefit from ICB, revealing an urgent need for identifying novel strategies for sensitizing patients to ICB. Previously, the authors demonstrated that type-I protein arginine methyltransferases (PRMTs) regulated antiviral innate-immune responses in TNBC by altering RNA splicing. This study aimed to explore the effects of targeting type-I PRMTs on the tumor microenvironment (TME) and the efficacy of ICB therapy against TNBC. METHODS: Single-cell transcriptomic analysis was performed to investigate the effects of type-I PRMT inhibition on the TME, especially T-cell subsets. Single-cell T-cell receptor sequencing was performed to analyze the diversity and dynamics of the T-cell repertoire. A syngeneic murine model of TNBC was used to evaluate the therapeutic efficacy and immune memory effect of combining a type-I PRMT inhibitor (MS023) with an anti-programmed cell death protein 1 (PD-1) antibody. RESULTS: Type-I PRMT inhibition combined with anti-PD-1 therapy reduced tumor growth. Mechanistically, type-I PRMT inhibition reshaped the TME. Increased CD8 T-cell infiltration was verified using flow cytometry. Increased clonotypes and clonal diversity were also observed after MS023 treatment, which contributed to immune memory following combination treatment. CONCLUSIONS: Targeting type-I PRMT can potentially improve immunotherapeutic efficacies in patients with TNBC. By enhancing the tumor immunogenicity and promoting a more favorable immune microenvironment, this combined approach may enable more patients with TNBC to benefit from immunotherapies.
20
Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text
Medicine, Oncology, Pharmacology +16
Sherene Loi, Nicolas Sirtaine, Fanny Piette et al. · Journal of Clinical Oncology · 2013 · 1.6K citations
Medicine, Immunology, Oncology +17
Peter Schmid, Hope S. Rugo, Sylvia Adams et al. · The Lancet Oncology · 2019 · 1.2K citations
Medicine, Oncology, Pharmacology +14